XML 206 R162.htm IDEA: XBRL DOCUMENT
v3.22.4

Liabilities related to business combinations and to non-controlling interests - Additional Information (Details) € in Millions | 12 Months Ended |  |  |  |
--- | --- | --- | --- | --- | ---
Dec. 31, 2022 USD ($) | Dec. 31, 2022 EUR (€) | Dec. 31, 2021 EUR (€) | Dec. 31, 2020 EUR (€) | Dec. 31, 2019 EUR (€)
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items] |  |  |  |  |
Fair value of contingent consideration payable |  | € 779 | € 714 | € 605 | € 800
Commitments relating to contingent consideration in connection with business combinations |  | 604 | 689 | 1,043 |
Bayer contingent consideration |  |  |  |  |
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items] |  |  |  |  |
Payment to sale of business period | 10 years |  |  |  |
Milestone payment period | 2021 |  |  |  |
Fair value of contingent consideration payable |  | € 26 | 59 | 104 |
Increase in fair value of liability |  | 1.00% |  |  |
Bayer contingent consideration | Top of range |  |  |  |  |
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items] |  |  |  |  |
Potentiel payments related to percentage of sales of alemtuzumab | $ | $ 1,250,000,000 |  |  |  |
MSD contingent consideration (European vaccines business) |  |  |  |  |
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items] |  |  |  |  |
Fair value of contingent consideration payable |  | € 204 | 269 | 312 |
Increase in fair value of liability |  | 1.00% |  |  |
Fair value of contingent consideration payable |  | € 204 | 269 | 312 | 385
Shire contingent consideration |  |  |  |  |
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items] |  |  |  |  |
Increase in fair value of liability |  | 13.00% |  |  |
Amunix |  |  |  |  |
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items] |  |  |  |  |
Increase in fair value of liability |  | 1.00% |  |  |
Fair value of contingent consideration payable |  | € 165 | € 0 | € 0 | € 0

X
- Definition The amount of contingent liabilities recognised in a business combination. [Refer: Contingent liabilities [member]; Business combinations [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2021-01-01 -Paragraph B67 -Subparagraph c -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B67_c&doctype=Appendix&subtype=B -URIDate 2021-03-24 + Details
Name: | ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Commitments Relating To Contingent Consideration In Connection With Business Combinations + References No definition available. + Details
Name: | sny_CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items] + References No definition available. + Details
Name: | sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems
Namespace Prefix: | sny_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fair value of the contingent consideration payable + References No definition available. + Details
Name: | sny_FairValueOfContingentConsiderationPayable
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Milestone payment term. + References No definition available. + Details
Name: | sny_MilestonePaymentTerm
Namespace Prefix: | sny_
Data Type: | xbrli:gYearItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payment to sale of business period. + References No definition available. + Details
Name: | sny_PaymentToSaleOfBusinessPeriod
Namespace Prefix: | sny_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage increase in fair value liabilities. + References No definition available. + Details
Name: | sny_PercentageIncreaseInFairValueLiabilities
Namespace Prefix: | sny_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Potentiel payments related to percentage of sales. + References No definition available. + Details
Name: | sny_PotentialPaymentsRelatedToPercentageOfSales
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=sny_BayerScheringPharmaAGMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=sny_ShireHumanGeneticTherapiesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=sny_AmunixMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |